Skip to Main Content

Peter Bach has another crazy idea.

Bach, the director for the center for health policy and outcomes at Memorial Sloan Kettering Cancer Center, thinks that biosimilars, the would-be cheaper alternatives to the biologic drugs that are among the industry’s most expensive, are a lost cause.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

Comments are closed.